The calibrated automated thrombogram as a clinical test for monitoring hypercoagulability in patients with cerebral venous sinus thrombosis.

Completed

Conditions: 10014523
venous sinus thrombosis
venous stroke
10064477

Registration Number: NL-OMON46638

Lead Sponsor: aboratory for Clinical Thrombosis and Haemostasis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

Inclusion criteria patient group:
Age above 18 years
Male and female
Radiologically proven sinus thrombosis in the past 3 years;Inclusion criteria control group:
*Inclusion criteria control group
Age above 18 years
Male and female

Exclusion Criteria

Exclusion criteria patient group:
Patients with known coagulation disorders
Patients with a malignancy
Patients on hormonal contraception or who receive other hormonal therapy
Current use of oral anticoagulants
Incapacitated/ mentally disabled subjects;Exclusion criteria control group:
Known coagulation disorders
Subjects with known malignancy
Use of oral hormonal contraception or other hormonal therapy
Current use of oral anticoagulants
Incapacitated/disabled subjects*

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcomes of the calibrated automated thrombogram are: lag time, time to<br /><br>peak, peak height, endogenous thrombin potential (area under the curve) and<br /><br>peak reduction. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>In addition, determinants which influence the coagulation cascade will be<br /><br>measured (i.e.: PT, aPTT, Thrombintime, Fibrinogen, Prothrombin, Anti-thrombin,<br /><br>Free tissue factor pathway inhibitor (TFPI), TFPI activity, Protein C, Free<br /><br>Protein S, Total Protein S, vWF activity, vWF antigen, FVIII activity, FVIII<br /><br>antigen, FV activity, FVII activity, FXI activity, FX activity, FXI activity,<br /><br>FXII activity, FXIII activity, a2-antiplasmin, PAI-1 activity). </p><br>